CEVEC Pharmaceuticals Opens US Subsidiary
|| Print ||
|Monday, 15 November 2010 08:45 (UTC + 1)|
Cologne, Germany, November 15, 2010 / b3c newswire / - CEVEC Pharmaceuticals, the developer of a novel human protein expression system derived from amniocytes, announced today the US expansion of it’s business by founding a North American subsidiary, CEVEC Pharmaceuticals, Inc., in Potomac, Maryland, USA.
Located close to Washington DC and amidst the Northeast US Bioscience Corridor, the incorporation of the new site reflects CEVEC ambition to better serve the growing US market.
„The largest global Life Science market is the United States“ stated Dr. Rainer Lichtenberger, CEO of CEVEC. „ Since we have now a significant number of license holders based in the US, the new expansion will allow us to provide high quality, fast and very focused customer service".
Wolfgang Kintzel, CCO of CEVEC added: „Gary Boch, VP Business Development, North America, a very experienced Life Science professional, will manage our US business. From Maryland (US) we will now have the chance to further establish the CAP technology as a key protein expression platform being closer to our key customers and business partners.“
CAP® cells are a human immortalized cell line derived from primary human amniocytes that meet highest ethical standards. CAP® cells grow in serum-free suspension cultures, allow stable protein production, and show human-like post-translational modifications and authentic human glycosylation patterns.
CAP® is a trademark of CEVEC Pharmaceuticals GmbH, all rights reserved.
About CEVEC Pharmaceuticals GmbH - www.cevec-pharmaceuticals.com